{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:23:03Z","timestamp":1785288183968,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T00:00:00Z","timestamp":1486944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.cct.2017.02.002","type":"journal-article","created":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T17:31:20Z","timestamp":1486402280000},"page":"56-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids"],"prefix":"10.1016","volume":"55","author":[{"given":"Christian","family":"Seitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017dana","family":"Bumbuliene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rosa","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskari","family":"Heikinheimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Heweker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hude\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Jacquemyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Benedetto","family":"Melis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Parashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Rechberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Cano","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"van Aken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Zatik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gemzell-Danielsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cct.2017.02.002_bb0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.cct.2017.02.002_bb0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.bpobgyn.2008.01.008","article-title":"Clinical presentation of fibroids","volume":"22","author":"Gupta","year":"2008","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.cct.2017.02.002_bb0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejogrb.2010.05.012","article-title":"The burden of uterine fibroids in five European countries","volume":"152","author":"Downes","year":"2010","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"1","key":"10.1016\/j.cct.2017.02.002_bb0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/01443610701814328","article-title":"Overview of current surgical management of fibroids: \u2018Organ-preserving modalities\u2019","volume":"28","author":"Elahi","year":"2008","journal-title":"J. Obstet. Gynaecol."},{"key":"10.1016\/j.cct.2017.02.002_bb0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejogrb.2015.08.034","article-title":"The incidence of hysterectomy, uterus-preserving procedures and recurrent treatment in the management of uterine fibroids","volume":"194","author":"Mart\u00edn-Merino","year":"2015","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"5","key":"10.1016\/j.cct.2017.02.002_bb0030","first-page":"300","article-title":"Uterine artery embolisation - a treatment alternative for women with fibroids","volume":"35","author":"Lyon","year":"2006","journal-title":"Aust. Fam. Physician"},{"issue":"4","key":"10.1016\/j.cct.2017.02.002_bb0035","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2005-2379","article-title":"A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells","volume":"91","author":"Chen","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cct.2017.02.002_bb0040","doi-asserted-by":"crossref","first-page":"436174","DOI":"10.1155\/2012\/436174","article-title":"Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo","volume":"2012","author":"Horak","year":"2012","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.cct.2017.02.002_bb0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/IJWH.S33125","article-title":"Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial","volume":"5","author":"Carbonell","year":"2013","journal-title":"Int. J. Womens Health"},{"issue":"5","key":"10.1016\/j.cct.2017.02.002_bb0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cct.2017.02.002_bb0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cct.2017.02.002_bb0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jmig.2005.01.022","article-title":"Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas","volume":"12","author":"Eisinger","year":"2005","journal-title":"J. Minim. Invasive Gynecol."},{"issue":"6","key":"10.1016\/j.cct.2017.02.002_bb0065","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/humrep\/dem026","article-title":"The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata","volume":"22","author":"Williams","year":"2007","journal-title":"Hum. Reprod."},{"issue":"6","key":"10.1016\/j.cct.2017.02.002_bb0070","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/uog.14668","article-title":"Influence of ulipristal acetate therapy compared with uterine artery embolization on fibroid volume and vascularity indices assessed by three-dimensional ultrasound: prospective observational study","volume":"45","author":"Czuczwar","year":"2015","journal-title":"Ultrasound Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.cct.2017.02.002_bb0080","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.cct.2017.02.002_bb0085","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","article-title":"Long-term medical management of uterine fibroids with ulipristal acetate","volume":"105","author":"Donnez","year":"2016","journal-title":"Fertil. Steril."},{"issue":"2","key":"10.1016\/j.cct.2017.02.002_bb0090","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertil. Steril."},{"issue":"6","key":"10.1016\/j.cct.2017.02.002_bb0095","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil. Steril."},{"issue":"8","key":"10.1016\/j.cct.2017.02.002_bb0100","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/humrep\/det247","article-title":"BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies","volume":"28","author":"Wagenfeld","year":"2013","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.cct.2017.02.002_bb0105","unstructured":"B. Rohde, C. Seitz, A. Kaiser, M. Schultze-Mosgau, B. Sch\u00fctt, Pharmacodynamic effects and safety of the novel selective progesterone receptor modulator vilaprisan. Available from: http:\/\/seud-congress.com\/files\/107\/COMM_2015\/SAMEDI\/H\/05._Beate_Rohde.pdf (Accessed 20 January 2017). Presented at the 1st SEUD Congress, Paris, France, 2015."},{"issue":"6","key":"10.1016\/j.cct.2017.02.002_bb0110","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.fertnstert.2013.08.028","article-title":"A new menstrual pictogram for use with feminine products that contain superabsorbent polymers","volume":"100","author":"Magnay","year":"2013","journal-title":"Fertil. Steril."},{"issue":"2","key":"10.1016\/j.cct.2017.02.002_bb0115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.fertnstert.2013.10.051","article-title":"Validation of a new menstrual pictogram (superabsorbent polymer-c version) for use with ultraslim towels that contain superabsorbent polymers","volume":"101","author":"Magnay","year":"2014","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.cct.2017.02.002_bb0120","unstructured":"K. Wichmann, M.S. Mattera, A. Filonenko, C. Seitz, M. Schaefers, J. Goldstein, C. Gerlinger, I. Wiklund, Assessing the patient-reported symptoms and impacts of uterine fibroids: development of Uterine Fibroid Daily Symptom Scale (UF-DSD) and Uterine Fibroid Impact Scale (UFIS). Available from: http:\/\/seud.org\/wp-content\/uploads\/2016\/05\/10-Wichmann.pdf (Accessed 20 January 2017). Presented at the 2nd SEUD Congress, Barcelona, Spain, 2016."},{"issue":"1\u20132","key":"10.1016\/j.cct.2017.02.002_bb0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jsbmb.2008.11.015","article-title":"Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system","volume":"113","author":"Afhuppe","year":"2009","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"6","key":"10.1016\/j.cct.2017.02.002_bb0130","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.contraception.2014.08.006","article-title":"A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception","volume":"90","author":"Huang","year":"2014","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.cct.2017.02.002_bb0135","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1210\/jc.2014-3344","article-title":"Neuroendocrine causes of amenorrhea\u2013an update","volume":"100","author":"Fourman","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cct.2017.02.002_bb0140","author":"ICH Harmonised Tripartite Guideline"},{"issue":"14","key":"10.1016\/j.cct.2017.02.002_bb0145","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1158\/1078-0432.CCR-08-0325","article-title":"Multi-arm clinical trials of new agents: some design considerations","volume":"14","author":"Freidlin","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.cct.2017.02.002_bb0150","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1471-0528.1990.tb16249.x","article-title":"Assessment of menstrual blood loss using a pictorial chart","volume":"97","author":"Higham","year":"1990","journal-title":"Br. J. Obstet. Gynaecol."},{"issue":"6","key":"10.1016\/j.cct.2017.02.002_bb0155","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0029-7844(97)00534-6","article-title":"Variation in the incidence of uterine leiomyoma among premenopausal women by age and race","volume":"90","author":"Marshall","year":"1997","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.cct.2017.02.002_bb0160","series-title":"Ulipristal Acetate (Fibristal) (5mg Tablets): Treatment of Moderate to Severe Signs and Symptoms of Uterine Fibroids in Adult Women of Reproductive Age Who are Eligible for Surgery. The Duration of Treatment is Limited to Three Months","author":"CADTH Common Drug Reviews","year":"2013"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416302270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714416302270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T15:08:18Z","timestamp":1589728098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714416302270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":31,"alternative-id":["S1551714416302270"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2017.02.002","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2017.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Bayer AG. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}